| 发明名称 | Modulation of activity of proneurotrophins | ||
| 摘要 | The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual. | ||
| 申请公布号 | US9234036(B2) | 申请公布日期 | 2016.01.12 |
| 申请号 | US201414262398 | 申请日期 | 2014.04.25 |
| 申请人 | H. Lundbeck A/S | 发明人 | Anderson Olav Michael;Nykjaer Anders |
| 分类号 | A61K38/40;A61K39/42;C07K16/26;C07K14/47;C07K14/705;G01N33/68;A61K38/07;A61K38/08;A61K38/10;A61K38/17;A61K39/395;C07K5/11;C07K7/06;C07K7/08;G01N33/566;A61K38/00;A61K39/00 | 主分类号 | A61K38/40 |
| 代理机构 | AuerbachSchrot LLC | 代理人 | Auerbach Jeffrey I.;AuerbachSchrot LLC |
| 主权项 | 1. A method of treating pain comprising administering to a subject in need thereof a therapeutically effective amount of an antibody that binds to: (1) residues 7-10 (RIFR) (SEQ ID NO:27); (2) residues 14-18 (FAKNF) (SEQ ID NO:28); or (3) residues 7-10 (RIFR) (SEQ ID NO:27) and residues 14-18 (FAKNF) (SEQ ID NO:28); of a Sortilin receptor that consists of the amino acid sequence of SEQ ID NO:25, wherein said pain is selected from the group consisting of cutaneous pain, somatic pain, visceral pain and phantom limb pain. | ||
| 地址 | Valby DK | ||